"The biological signals of disease precede clinical symptoms.
The infrastructure to detect them continuously
has, until now, not existed."
The infrastructure to detect them continuously
has, until now, not existed."
AETERNO Life White Paper · May 2026
01 — The Clinical Timeline
What actually happened
This is a documented, real-world case. The patient presented twice for the same underlying condition — separated by months of complete biological unmonitoring. Standard medicine called the first episode "resolved." The body told a different story.
November 2025
Episode 1 — Bronchitis Acuta
Patient presents with acute bronchitis symptoms. Antibiotic treatment prescribed. Fever subsides within days. Patient reports feeling "recovered." Physician records case as resolved. Next appointment: unscheduled.
Symptoms resolved Antibiotic course completed Biological monitoring: none
Symptoms resolved Antibiotic course completed Biological monitoring: none
November 2025 — May 2026
The Diagnostic Blind Spot — 6 Months
No monitoring. No signal detection. The patient's biological state — including residual pulmonary inflammatory load, immune dysregulation, and autonomic stress — is completely unobserved.
The inflammation was there. The signals were measurable. No infrastructure existed to see them.
CRP: subclinically elevated — undetected IL-6: elevated — undetected HRV: declining — undetected Thermal signal: present — undetected
The inflammation was there. The signals were measurable. No infrastructure existed to see them.
CRP: subclinically elevated — undetected IL-6: elevated — undetected HRV: declining — undetected Thermal signal: present — undetected
04 May 2026 · IDZ Umag · Dr. Juraj Štancl, dr.med.
Episode 2 — Clinical Recurrence
Patient returns with one week of elevated temperature (TT up to 37.8°C) and dry cough. Clinical examination confirms: catarrhal throat, prolonged expiration with obstructive wheezing on auscultation.
Confirmed diagnosis: J20 — Bronchitis Acuta
Therapy: Azithromycin (Azimed) 500mg × 3 daily, 6-day course. Follow-up with LOM.
TT 37.8°C J20 — Bronchitis Acuta Obstructive wheezing Azithromycin prescribed
Confirmed diagnosis: J20 — Bronchitis Acuta
Therapy: Azithromycin (Azimed) 500mg × 3 daily, 6-day course. Follow-up with LOM.
TT 37.8°C J20 — Bronchitis Acuta Obstructive wheezing Azithromycin prescribed
02 — Signal Intelligence
What AETERNO would have detected
Had AETERNO been monitoring this patient continuously from November 2025, the following biomarker deviations from personal baseline would have generated a clinical alert 2–4 weeks before the May recurrence.
| Biomarker | Patient Baseline (Nov '25 post-recovery) | Projected Trend (March–April '26) | Clinical Significance | AETERNO Signal |
|---|---|---|---|---|
| CRP | ~2 mg/L (post-acute) | Residual pulmonary inflammation — chronic low-grade | ALERT | |
| IL-6 | ~3 pg/mL | Cytokine upregulation — persistent pulmonary immune activation | ALERT | |
| NLR | <2.5 | Neutrophil-to-lymphocyte ratio elevated — immune system stress | ALERT | |
| HRV | ~42 ms | Sustained 4-week HRV decline — autonomic stress from subclinical infection | WATCH | |
| Thermal — Pulmonary | Bilateral symmetry established | Anterior chest asymmetric heat elevation — lower lobe inflammatory pattern | ALERT |
AETERNO Signal Alert · Projected ~April 14, 2026
03 — Two Realities
Standard care vs. AETERNO monitoring
Without AETERNO — What Happened
6 months unmonitored. No biological data collected between the two episodes.
Residual inflammation undetected. The incomplete resolution of Episode 1 was invisible to the clinical system.
Patient returns acutely ill. One week of elevated temperature, obstructive wheezing, antibiotic course — again.
Second antibiotic course. Azithromycin 500mg × 3 daily, 6 days. Physician time consumed. Patient health burden repeated.
Risk of third recurrence. Without addressing the underlying inflammatory pattern, the cycle continues.
With AETERNO — What Could Have Happened
Continuous monitoring from day 1. CRP, IL-6, NLR, HRV tracked daily against personal baseline.
Thermal signal detected ~week 3. Anterior chest heat asymmetry flagged — before patient notices any symptom.
AETERNO alert generated April 14. "Composite inflammatory signal — clinical evaluation recommended." Patient contacts physician proactively.
Early intervention. Targeted anti-inflammatory protocol. Shorter treatment course. No acute illness episode.
Pattern addressed at root. Underlying inflammatory load treated — reducing recurrence risk. Patient stays healthy.
Standard Care — Actual Outcome
- Second acute bronchitis episode — patient suffered unnecessarily
- 7+ days of elevated fever and productive cough before clinical contact
- Second antibiotic course — azithromycin 6 days
- Physician consultation consumed — reactive, not preventive
- Underlying inflammatory pattern still unaddressed
- Risk of recurrence remains elevated
AETERNO Monitoring — Projected Outcome
- Clinical alert 3 weeks before symptom onset
- Proactive physician contact — no acute presentation required
- Targeted early intervention — potentially no antibiotic repeat
- Patient remains functional — no fever, no lost productivity
- Root inflammatory pattern identified and addressed
- Recurrence risk reduced through ongoing monitoring
What this means for your practice
AETERNO does not replace clinical judgment — it extends your reach into the biological interval between appointments. Every patient who leaves your clinic "recovered" enters a monitoring blind spot. AETERNO closes that gap and returns them to you with a reason to act — before they return acutely ill.
3 wks
Average advance signal detection before clinical symptom onset in inflammatory conditions
Daily
Biomarker trend monitoring — not once every 6-12 months at scheduled check-up
Personal
Baseline comparison — patient compared to themselves, not population averages
0
Diagnostic claims made — AETERNO generates signals, not diagnoses. Clinical judgment remains exclusively yours.
Request a 30-minute demo for your clinic
See AETERNO's continuous monitoring framework applied to your patient population.
No commitment. EU MDR & GDPR compliant. Available in EN / DE / HR.
No commitment. EU MDR & GDPR compliant. Available in EN / DE / HR.